Prescribing patterns of glucosamine in an older population: a national cohort study

BMC Complementary and Alternative Medicine

Tom Fahey³  Kathleen Bennett¹  Nicola Motterlini³  Fiona Boland³  Grainne Cousins²  Rose Galvin³ 

[1] Department of Pharmacology and Therapeutics, Trinity College Dublin, Dublin, Ireland;School of Pharmacy, Royal College of Surgeons in Ireland, Dublin, Ireland;HRB Centre for Primary Care Research, Department of General Practice, Royal College of Surgeons in Ireland, Dublin, Ireland

关键词: Cost-effectiveness;    Glucosamine;    Osteoarthritis;   

Others  :  1220524
DOI  :  10.1186/1472-6882-13-316

 received in 2012-12-21, accepted in 2013-11-06,  发布年份 2013

【 摘 要 】

Background

Glucosamine is commonly prescribed as a disease modulating agent in osteoarthritis. However, the evidence to date suggests that it has a limited impact on the clinical symptoms of the disease including joint pain, radiological progression, function and quality of life. The aim of this study was to examine the prescribing patterns of glucosamine from 2002–2011 in an elderly Irish national population cohort using data from the Health Service Executive Primary Care Reimbursement (HSE-PCRS) General medical services (GMS) Scheme.

Methods

Patients aged ≥ 70 years on the HSE-PCRS pharmacy claims database between January 2002 and December 2011 were included. ATC code M01AX05 (glucosamine) was extracted. Prevalence rates per 1000 eligible population with 95% confidence intervals were calculated for all years and age groups (70–74 years, ≥75 years). A negative binomial regression analysis was used to determine longitudinal usage trends and compare prevalence rates across years, sex and age groups.

Results

The annual patient rate of glucosamine prescribing increased significantly from 13.0/1000 eligible population (95% CI 12.6-13.4) in 2002 to 68.7/1000 population (95% CI 67.8-69.5) in 2009 before decreasing to 62.4/1000 population (95% CI 61.6-63.2) in 2011. The rate of prescribing of glucosamine varied with sex, with women receiving significantly more prescriptions than men. The cost of glucosamine also increased from 2002–2008. In 2008 total expenditure reached a high of €4.6 million before decreasing to €2.6 million in 2011.

Conclusion

The national trend in prescribing of glucosamine increased significantly from 2002 to 2009 before decreasing in 2010 and 2011, in keeping with current international guidelines. There is a need for awareness among healthcare professionals and patients alike of the best available evidence to inform decision making relating to the prescription and consumption of such supplements.

【 授权许可】

   
2013 Galvin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Facts about arthritis http://www.arthritisireland.ie webcite
• [2]Seed S, Dunican K, Lynch AM: Osteoarthritis: a review of treatment options. Geriatrics 2009, 64(10):20-29.
• [3]Wandel S, Juni P, Tendal B, Nuesch E, Villiger P, Welton N, Reichenbach S, Trelle S: Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010, 341:c4675.
• [4]Gigante A, Callegari L: The role of intra-articular hyaluronan (Sinovial) in the treatment of osteoarthritis. Rheumatol Int 2011, 31(4):427-444.
• [5]Towheed T, Maxwell L, Anastassiades TP, Shea B, Houpt JB, Welch V, Hochberg MC, Wells GA: Glucosamine therapy for treating osteoarthritis. Cochrane Database of Syst Rev 2005., 2CD002946
• [6]Vlad SC, LaValley MP, McAlindon TE, Felson DT: Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum 2007, 56(7):2267-2277.
• [7]Lopez Fernandez JC, Ruano-Ravina A: Efficacy and safety of intraarticular hyaluronic acid in the treatment of hip osteoarthritis: a systematic review. Osteoarthritis Cartilage 2006, 14(12):1306-1311.
• [8]Reichenbach S, Sterchi R, Scherer M, Trelle S, Burgi E, Burgi U, Dieppe PA, Juni P: Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007, 146(8):580-590.
• [9]National Institute for Health and Clinical Excellence: Osteoarthritis: the care and management of osteoarthritis in adults. London: National Collaborating Centre for Chronic Conditions; 2008.
• [10]Richmond J, Hunter D, Irrgang J, Jones MH, Snyder-Mackler L, Van Durme D, Rubin C, Matzkin EG, Marx RG, Levy BA, et al.: American Academy of Orthopaedic Surgeons clinical practice guideline on the treatment of osteoarthritis (OA) of the knee. J Bone Joint Surg Am 2010, 92(4):990-993.
• [11]US glucosamine grows slow, lags global sales http://www.nutraingredients-usa.com/Markets/US-glucosamine-grows-slow-lags-global-sales webcite
• [12]Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K: Potentially inappropriate prscribing and cost outcomes for older people: a national population study. B Clin Pharmacol 2010, 69(5):543-552.
• [13]Naughton C, Bennett K, Feely J: Prevalence of chronic disease in the elderly based on a national pharmacy claims database. Age Ageing 2006, 35(6):633-636.
• [14]Irish Medicines Formulary: Irish medicines formulary report. Ireland: Selected Issues; 2012. Dublin 2012
• [15]WHO Collaborating Centre for Drug Statistics Methodology: Anatomical Therapeutic Chemical (ATC) Classification Index. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2007.
• [16]Clegg DO, Reda DJ, Harris CL, Klein MA, O’Dell JR, Hooper MM, Bradley JD, Bingham COI, Weisman MH, Jackson CG, et al.: Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006, 354(8):795-807.
• [17]Sibbritt D, Adams J, Lui CW, Broom A, Wardle J: Who uses glucosamine and why? A study of 266,848 Australians aged 45 years and older. PloS One 2012, 7(7):e41540.
• [18]NSAIDs and analgesics national charts http://www.nhsbsa.nhs.uk/PrescriptionServices/2585.aspx webcite
• [19]Carlsen B, Glenton C, Pope C: Thou shalt versus thou shalt not: a meta-synthesis of GPs’ attitudes to clinical practice guidelines. B J Gen Pract 2007, 57(545):971-978.
• [20]Barry M: Economic evaluation of glucosamine sulfate (DONA®) for the treatment of osteoarthritis in the Irish Healthcare setting. http://www.ncpe.ie/wp-content/uploads/2009/07/Economic-evaluation-of-glucosamine-sulphate-summary.pdf webcite
• [21]Bishop F, Lewith G: Who uses CAM? A narrative review of demographic characteristics and health factors associated with CAM use. Evid Based Complement Alternat Med 2010, 7(1):11-28.
• [22]Chung V, Ma P, Lau C, Wong S, Yeoh E, Griffiths S: Views on traditional Chinese medicine amongst Chinese population: a systematic review of qualitative and quantitative studies. Health Expect 2012. in press
• [23]Barnes PM, Bloom B, Nahin RL: Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008, 10(12):1-23.
• [24]Wazaify M, Shields E, Hughes CM, McElnay JC: Societal perspectives on over-the-counter (OTC) medicines. Fam Pract 2005, 22(2):170-176.
• [25]Tsui T, Boon H, Boecker A, Kachan N, Krahn M: Understanding the role of scientific evidence in consumer evaluation of natural health products for osteoarthritis an application of the means end chain approach. BMC Complement Altern Med 2012, 12(1):198. BioMed Central Full Text